Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Capital Expenditures (2020 - 2024)

Ovid Therapeutics' Capital Expenditures history spans 5 years, with the latest figure at $41000.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures fell 41.43% year-over-year to $41000.0; the TTM value through Sep 2025 reached $41000.0, down 65.55%, while the annual FY2024 figure was $90000.0, 7.22% down from the prior year.
  • Capital Expenditures reached $41000.0 in Q4 2024 per OVID's latest filing, up from -$67000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $853100.0 in Q3 2022 to a low of -$87602.0 in Q4 2020.
  • Average Capital Expenditures over 5 years is $86131.4, with a median of $30767.0 recorded in 2020.
  • Peak YoY movement for Capital Expenditures: skyrocketed 3768.93% in 2022, then plummeted 1216.67% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$87602.0 in 2020, then skyrocketed by 284.88% to $161958.0 in 2021, then decreased by 25.94% to $119939.0 in 2022, then plummeted by 41.64% to $70000.0 in 2023, then plummeted by 41.43% to $41000.0 in 2024.
  • Per Business Quant, the three most recent readings for OVID's Capital Expenditures are $41000.0 (Q4 2024), -$67000.0 (Q3 2024), and $97000.0 (Q2 2024).